BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28
• 31

• Press Releases

  Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

  March 21, 2025

   · 

  1 min read
• 

  Business

  Adaptimmune Raises ‘Substantial Doubt’ About Business Despite First-in-Class T Cell Therapy

  Adaptimmune is rolling out its T cell therapy Tecelra for synovial sarcoma, recording $1.2 million in sales since its approval in August 2024. Nevertheless, it is pausing development of two oncology assets to save money.

  March 21, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Vaccines

  CDC Vaccine Advisors to Meet in April as Trump Eyes New Agency Director

  After withdrawing its nomination for Dave Weldon last week, the Trump administration is now reportedly considering Texas Republican Michael Burgess to head the Centers for Disease Control and Prevention.

  March 21, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  FDA

  J&J Wins Crohn’s Expansion for Tremfya as Stelara Biosimilars Enter US Market

  The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar challenge.

  March 21, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Syneron Bio Announces Strategic Collaboration with AstraZeneca

  March 21, 2025

   · 

  1 min read
• Press Releases

  iECURE Announces Presentation of Full Data for the First Infant Dosed with ECUR-506 in OTC-HOPE Phase 1/2 Clinical Trial at the 2025 ACMG Annual Clinical Genetics Meeting

  March 21, 2025

   · 

  6 min read
• Press Releases

  BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

  March 21, 2025

   · 

  1 min read
• Press Releases

  Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones

  March 21, 2025

   · 

  4 min read
• 

  Manufacturing

  J&J Joins Pharma Peers With $55B US Manufacturing Boost Following Trump’s Tariff Threats

  Johnson & Johnson follows Eli Lilly in spending billions on U.S. manufacturing after President Donald Trump threatened major tariffs on pharmaceutical products. Pfizer has also promised a similar commitment.

  March 21, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Rare diseases

  Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease

  This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.

  March 21, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky